June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Ocular Surface Changes in Glaucomatous Patients Treated with and without Preservatives beta-Blockers
Author Affiliations & Notes
  • Serena Telani
    University Eye Clinic, Genova, Italy
  • Michele Iester
    University Eye Clinic, Genova, Italy
  • Paolo Frezzotti
    University Eye Clinic, Siena, Italy
  • Michele Figus
    University Eye Clinic, Pisa, Italy
  • Paolo Fogagnolo
    University Eye Clinic, Milano, Italy
  • Andrea Perdicchi
    University Eye Clinic, La Sapienza, Rome, Italy
  • Antonio Ferreras
    Univerisity Eye Clinic, Zaragoza, Spain
  • Carlo Enrico Traverso
    University Eye Clinic, Genova, Italy
  • Footnotes
    Commercial Relationships Serena Telani, None; Michele Iester, None; Paolo Frezzotti, None; Michele Figus, None; Paolo Fogagnolo, None; Andrea Perdicchi, None; Antonio Ferreras, Alcon Laboratories, Inc (R), Allergan, Inc (R), Carl Zeiss Meditec (C), Heidelberg Engineering (F), Instituto Salud Carlos III (F), Novartis (R), Oculus, Inc (F); Carlo Enrico Traverso, MSD (F), Alcon (F), Santen (F), Thea (F), Allergan (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5427. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Serena Telani, Michele Iester, Paolo Frezzotti, Michele Figus, Paolo Fogagnolo, Andrea Perdicchi, Antonio Ferreras, Carlo Enrico Traverso, beta-blocker study group; Ocular Surface Changes in Glaucomatous Patients Treated with and without Preservatives beta-Blockers. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5427.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine whether there were ocular surface changes in glaucomatous patients treated with preservatives beta-blockers who switched to preservative-free beta-blockers.

Methods: This was prospective and longitudinal study. 132 patients with POAG treated with a preserved beta blocker were enrolled. All the patients underwent perimetric and gonioscopic examination, complete ophthalmologic examination, IOP measurements, evaluation of ocular surface, Schirmer test, blood pressure and heart rate at baseline and 1-3 months after changing medical treatment to a preservative-free timolol 0.1% (Timogel 0.1, Thea). At baseline and at the end of the study, all patients underwent the Ocular Surface Disease Index (OSDI) questionnaire. Data were analyzed by t test when the distribution of the data was normal, by Mann-Whitney when the distribution was not-normal.

Results: No significant difference was found for IOP before switching from preserved beta-blockers to preservative-free ones. No significant difference was found in blood pressure and heart rate. However a statistically significant difference was found for abnormal fluorescein staining of cornea and conjunctiva, eyelid erythema, conjunctival hyperaemia and follicular hyperplasia. A significant difference was found for break-up time (from 9.38 ± 4.7 sec at baseline to 10.64 ± 4.7 after 3 months) and Schirmer’s test (from 12.9 ± 5.96 mm at baseline to 14.2 ± 5.87 mm after 3 months). OSDI questionnaire showed that the patient improved the dryness and foreign body sensation.

Conclusions: Preservative-free timolol 0.1 treatment maintained IOP at the same level of the other beta-blockers, but it was better tolerated in patients having signs or symptoms while on preserved beta blockers. Preservative-free treatment improved the quality of life reducing dryness, hyperaemia, follicular hyperplasia and foreign body sensation.

Keywords: 503 drug toxicity/drug effects • 486 cornea: tears/tear film/dry eye • 568 intraocular pressure  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.